|
Endpoint
|
Patients achieving endpoint, n/N (%)
|
|---|
|
95% CI
|
|---|
|
At week 24 visit
|
Up to week 24 visit
|
At end of treatment
|
Up to end of treatment
|
|---|
|
≥35% spleen volume reduction by MRI
|
4/17 (23.5)
|
5/23 (21.7)
|
4/23 (17.4)
|
7/23 (30.4)
|
|
95% CI 6.8–49.9
|
95% CI 5.0–38.8
|
|
≥50% spleen length reduction by physical examination
|
9/19 (47.4)
|
12/31 (38.7)
|
9/31 (29.0)
|
12/31 (38.7)
|
|
95% CI 24.4–71.1
|
95% CI 14.2–48.0
|
|
≥50% reduction in MF Quality of Life and Symptom Assessment total symptom score
|
7/18 (38.9)
|
12/29 (41.4)
|
4/29 (13.8)
|
12/29 (41.4)
|
-
aPatients included in the efficacy evaluable population are those who had both a non-missing baseline measurement and post-baseline measurement at or through the time point specified
-
MRI magnetic resonance imaging
